CMB.TECH is now a highly leveraged play on freight rates, with over 80% spot exposure post-merger and tripled operating scale. Reported EPS is distorted by one-off Golden Ocean deal costs; normalized earnings and EBITDA provide a clearer view of CMBT's true earnings power. CMBT's valuation and investment case hinge on freight rate sensitivity, with current market cap implying mid-to-high cycle TCE rates ($35k–45k/day).
CMB.TECH ANNOUNCES FINAL YEAR RESULTS ANTWERP, Belgium, 31 March 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” of “the company” (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its final financial results today for the full year ended 31 December 2025. HIGHLIGHTS 2025 Financial highlights: Profit of USD 89.1 million in Q4 2025 bringing full year profit to USD 139.1 million No major changes compared to the preliminary figures published on 26/2/26 Total contract backlog increased to USD 3.05 billion Fleet highlights: CMB.TECH focused on its fleet rejuvenation with 17 newbuild deliveries 8 Newcastlemaxes 1 Crude oil tanker 1 Chemical tanker 5 CTVs 2 CSOVs Further fleet expansion with 9 vessels ordered (6 chemical tankers, 2 CTVs and 1 MP-ASV) Sale of 12 older vessels (5 VLCCs, 2 Suezmaxes, 2 Capesizes, 2 Panamaxes and 1 CTV) Fortescue and CMB.TECH signed agreement for ammonia-powered Newcastlemax CMB.TECH and MOL signed landmark agreement for nine ammonia-powered vessels Corporate highlights: On March 4 2025, CMB.TECH announced that it entered into a share purchase agreement with Hemen Holding Limited for the acquisition of 81,363,730 shares in Golden Ocean Group Limited.
New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™ Amplification Kits leverage sequential and enhanced layered amplification (seqLA™) technology enabling improved detection of low-abundance and challenging targets.
Shares of Bio-Techne Corp (NASDAQ: TECH - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the fifteen ratings firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and one has given a strong buy
TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and competition cloud near-term outlook.
Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The position was previously 2.3% of the fund's AUM as of the prior quarter.
Representative April McClain Delaney (Democratic-Maryland) recently sold shares of CDW Corporation (NASDAQ: CDW). In a filing disclosed on March 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in CDW stock on February 24th. Representative April McClain Delaney also recently made the following trade(s): Purchased $1,001 - $15,000 in shares of EMCOR Group
Representative April McClain Delaney (Democratic-Maryland) recently bought shares of Rollins, Inc. (NYSE: ROL). In a filing disclosed on March 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Rollins stock on February 18th. Representative April McClain Delaney also recently made the following trade(s): Purchased $1,001 - $15,000 in shares of EMCOR Group
Representative April McClain Delaney (Democratic-Maryland) recently bought shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW). In a filing disclosed on March 10th, the Representative disclosed that they had bought between $15,001 and $50,000 in C.H. Robinson Worldwide stock on February 13th. Representative April McClain Delaney also recently made the following trade(s): Purchased $1,001 - $15,000 in
Representative April McClain Delaney (Democratic-Maryland) recently sold shares of The Middleby Corporation (NASDAQ: MIDD). In a filing disclosed on March 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Middleby stock on February 11th. Representative April McClain Delaney also recently made the following trade(s): Purchased $1,001 - $15,000 in shares of EMCOR
